Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qPCR, luciferase reporter assay, Western blot, etc. |
| Sample | adjacent normal tissues. Human ovarian cancer cell lines (OVCAR?3, SKOV3, 3AO, ES?2, HO?8910, A2780, COC1). |
| Expression Pattern | down-regulated |
| Function Description | To the best of our knowledge, this is the first study to report that GAS5 exerts inhibitory effects on ovarian cancer cell proliferation, at least in part through the downregulation of miR-21 expression and therefore the upregulation of SPRY2 expression. These findings suggest that the GAS5/miR?21/SPRY2 signaling pathway may be a potential therapeutic target in ovarian cancer. |
| Pubmed ID | 29896229 |
| Year | 2018 |
| Title | Long non-coding RNA GAS5 inhibits ovarian cancer cell proliferation via the control of microRNA-21 and SPRY2 expression. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |